DUBLIN, Oct. 3, 2019 /PRNewswire/ -- Allergan plc,
(NYSE: AGN), a leading global pharmaceutical company with a more
than 70-year heritage in ophthalmology, will present new data from
investigational Abicipar and Bimatoprost Sustained Release (SR) at
the Annual Meeting of the American Academy of Ophthalmology (AAO)
to be held in San Francisco,
California. The Retina Subspecialty Day (October 11-12) will feature a late-breaker
presentation on two-year data from the CEDAR and SEQUOIA clinical
studies of Abicipar in patients with neovascular age-related
macular degeneration (nAMD). Data will also be presented during a
paper session on October
14th for Bimatoprost SR, which has the potential
to be a first-in-class sustained-release, biodegradable implant for
the reduction of intraocular pressure (IOP) in patients with ocular
hypertension or open-angle glaucoma, including topline results
from two Phase 3 studies in open-angle glaucoma and ocular
hypertension. Additional company-sponsored data will also be
presented at the meeting as ePosters.
"The data presented at AAO for our late stage, investigational
assets, Abicipar and Bimatoprost Sustained-Release, showcase our
continued commitment to innovation in ophthalmology," said
Yehia Hashad, M.D., Senior Vice
President, Head of Global Clinical Development Allergan. "We're
excited to share data that may redefine treatment approaches in
neovascular age-related macular degeneration and glaucoma, and may
improve upon the current state of patient care."
Allergan will present four abstracts, including two oral
presentations and two ePoster presentations (all noted in local
Pacific Time):
Retina Subspecialty Day, Late Breaking – RET 11 - Section
VIII: Late Breaking Developments, Part I (Friday, October
11, 4:18 – 4:58 PM):
- Abicipar for Neovascular Age‐related Macular Degeneration:
Two-Year Results from CEDAR and SEQUOIA Phase 3 Clinical
Trials
-
- Author: Khurana R.
- Time: 4:34 – 4:39 PM
OP09 Glaucoma Original Papers Session (Monday, October 14, 2:00 – 5:15 PM):
- Phase 3 Evaluation of Bimatoprost Sustained-Release Implant in
Patients With Glaucoma or Ocular Hypertension: Results at Primary
Database Lock
-
- Authors: Craven ER et al.
- Time: 2:12 – 2:24 PM
Retina ePoster Presentations:
- Cumulative Retinal Fluid Exposure Reduces Visual Acuity Gain
During Anti-VEGF Therapy. An Analysis of CATT 2-Year Data
-
- Early vs Late Switch to Dexamethasone Intravitreal Implant in
Anti-VEGF Nonresponders with Diabetic Macular Edema in the
AUSSIEDEX Study
-
- Authors: Mitchell P et al.
About Allergan Eye Care
As a leader in eye
care, Allergan has discovered, developed, and delivered
some of the most innovative products in the industry for more than
70 years. Allergan has launched over 125 eye care
products and invested billions of dollars in new treatments for the
most prevalent eye conditions including glaucoma, ocular surface
disease, and retinal diseases such as diabetic macular edema and
retinal vein occlusion. Our eye care pipeline includes 13
additional agents for multiple ocular conditions.
Our commitment to the well-being of patients is also reflected
in philanthropy. Allergan and The Allergan
Foundation support more than 150 organizations around the
world working to improve lives and communities. We remain
steadfast in helping eye care providers deliver the best in patient
care through innovative products and outreach programs.
About Allergan plc
Allergan plc (NYSE: AGN),
headquartered in Dublin, Ireland, is a global pharmaceutical leader
focused on developing, manufacturing and commercializing branded
pharmaceutical, device, biologic, surgical and regenerative
medicine products for patients around the
world. Allergan markets a portfolio of leading brands and
best-in-class products primarily focused on four key therapeutic
areas including medical aesthetics, eye care, central nervous
system and gastroenterology. As part of its approach to delivering
innovation for better patient care, Allergan has built
one of the broadest pharmaceutical and device research and
development pipelines in the industry.
With colleagues and commercial operations located in
approximately 100 countries, Allergan is committed to
working with physicians, healthcare providers and patients to
deliver innovative and meaningful treatments that help people
around the world live longer, healthier lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained
in this press release that refer to future events or other
non-historical facts are forward-looking statements that reflect
Allergan's current perspective on existing trends and information
as of the date of this release. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the difficulty of predicting the timing or
outcome of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; the impact of uncertainty
around timing of generic entry related to key products, including
RESTASIS®, on our financial results; risks associated with
divestitures, acquisitions, mergers and joint ventures; risks
related to impairments; uncertainty associated with financial
projections, projected cost reductions, projected debt reduction,
projected synergies, restructurings, increased costs, and adverse
tax consequences; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Annual Report on Form 10-K
for the year ended December 31, 2018
and Allergan's Quarterly Report on Form 10-Q for the period ended
June 30, 2019. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements.
CONTACTS: Allergan:
Investors:
Manisha Narasimhan, PhD
(862) 261-7162
Media:
Fran DeSena
(862) 261 8820
Lisa Kim
(714) 246-3843
View original content to download
multimedia:http://www.prnewswire.com/news-releases/allergan-to-showcase-late-stage-data-in-age-related-macular-degeneration-and-glaucoma-at-american-academy-of-ophthalmology-annual-meeting-300930350.html
SOURCE Allergan plc